Skip to main content

Log In Create an account

Products & Services
Back to menu
Explore
- About Our Products & Services
- Our Tests
  Back to menu
  Our Tests
  
  Compare Our Tests
  
  FoundationOne CDx
  
  FoundationOne Liquid
  
  FoundationOne Heme
  
  IHC Testing
- Provider Services
  Back to menu
  Provider Services
  
  Overview
  
  Online Ordering & Report Integrations
  
  Clinical Research & Trial Matching
  
  Decision Support
- Biopharma Partner Services
  Back to menu
  Biopharma Partner Services
  
  Overview
  
  Genomic Data Solutions
  
  Clinical Trial Solutions
  
  Companion Diagnostic Development & Commercialization
- Actionable Results
Latest CDx Indication

Our FoundationOne®CDx tissue-based test now includes a pan-tumor companion diagnostic claim for a new indication of Keytruda® (pembrolizumab), for the identification of TMB-H patients (≥ 10 mutations/megabase) with unresectable or metastatic solid tumors.¹
Resource Center
Back to menu
Explore
Latest CDx Indication

Our FoundationOne®CDx tissue-based test now includes a pan-tumor companion diagnostic claim for a new indication of Keytruda® (pembrolizumab), for the identification of TMB-H patients (≥ 10 mutations/megabase) with unresectable or metastatic solid tumors.¹
News & Events
Back to menu
Explore
Useful Information
About Us
Back to menu
About Us
Useful Information
Careers
For Patients
Order a Test

Blog

View

News & Events Overview
Press Releases
Blog
Events
Media Library

Products & Services
Our Tests
Provider Services
Biopharma Partner Services

News & Events
Press Releases
Blog
Events

About Us
Our Story
Leadership Team
Careers

Contact Us
Login
Order a Test

© 2020 FOUNDATION MEDICINE, INC.

Legal & Privacy
California Compliance
Licenses